Premium
Reactivation of hepatitis B virus in a patient with adult T ‐cell leukemia–lymphoma receiving the anti‐ CC chemokine receptor 4 antibody mogamulizumab
Author(s) -
Nakano Nobuaki,
Kusumoto Shigeru,
Tanaka Yasuhito,
Ishida Takashi,
Takeuchi Shogo,
Takatsuka Yoshifusa,
Akinaga Shiro,
Mizokami Masashi,
Ueda Ryuzo,
Utsunomiya Atae
Publication year - 2014
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12117
Subject(s) - hepatitis b virus , medicine , ccr4 , virology , lymphoma , antibody , immunology , cc chemokine receptors , hepatitis b , chemokine receptor , virus , chemokine , immune system
The introduction of molecularly targeted drugs has increased the risk of reactivation of hepatitis B virus ( HBV ), which is a potentially fatal complication following anticancer chemotherapy even in patients who have previously resolved their HBV infection. CC chemokine receptor 4 ( CCR4 ) has been identified as a novel molecular target in antibody therapy for patients with adult T ‐cell leukemia–lymphoma ( ATL ) and peripheral T ‐cell lymphoma, and the humanized anti‐ CCR4 monoclonal antibody mogamulizumab has been developed. We reported HBV reactivation of an ATL patient with previously resolved HBV infection after mogamulizumab treatment in a dose‐finding study for this antibody. Our retrospective analysis using preserved samples also revealed the detailed kinetics of HBV DNA levels before and just after HBV reactivation.